Women Health Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 Global Women's Health Diagnostics Market was valued at $13,133 million in 2016, and is projected to reach $21,501 million at a CAGR of 7.0% from 2017 to 2023. Women are more prone to certain diseases, mostly related to menstrual disorders, depression, osteoporosis, obesity, and autoimmune diseases. Women's major health issues are related to the reproductive system that includes infertility, polycystic ovarian syndrome, menopause, and cancers such as breast cancer, cervical cancer, and urological disorders. Rise in geriatric female population, increase in incidence of chronic and lifestyle disorders, demand for point of care diagnostic testing, and high adoption of diagnostics imaging procedures. Moreover, numerous government initiatives to promote women health awareness also drives the market growth. However, the market growth is limited by high cost of diagnostics tests and dearth of skilled professionals. Conversely, surge in demand for the development of miniature diagnostic devices, rise in healthcare infrastructure, and creative marketing initiatives by key vendors in emerging countries are expected to provide lucrative opportunities for the market expansion during the forecast period.
Access Full Sample Report : https://goo.gl/F6HgsB The global women's health diagnostics market is segmented based on type, end user, and region. Based on type, the market is divided into diagnostic devices, diagnostic tests, and accessories and consumables. The devices segment is further segmented into biopsy devices and imaging and monitoring system. Imaging and monitoring systems segment is further segmented into ultrasound imaging systems, mammography systems, MRI systems, and nuclear imaging. Ultrasound imaging systems is further sub segmented into OB/GYN ultrasound and breast ultrasound. Mammography systems are further categorized as analog mammography systems, digital mammography systems, and breast tomosynthesis system. Tests segment is further categorized as breast cancer testing, cervical cancer testing, prenatal genetic screening and carrier testing, pregnancy and ovulation testing, and ovarian cancer testing. Breast cancer testing is further segmented into hormone receptor test, immunohistochemistry test, and other tests. Cervical cancer testing is bifurcated into PAP smear and HPV test. Prenatal genetic screening and carrier testing include tests for cystic fibrosis and other diseases. The pregnancy and ovulation testing segment is further bifurcated into lab-based pregnancy and ovulation testing, and home-based pregnancy and ovulation testing. Depending on end user, it is categorized into hospitals and clinics, home care settings,